Inhibrx Biosciences, Inc. (INBX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Inhibrx Biosciences, Inc. (INBX) closed at USD 85.26 on 2026-10-14, a change of +24.5 % over the past year, with a market capitalization of USD 1.33B.

Inhibrx Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Inhibrx Biosciences, Inc. key figures

Previous close

USD 85.26 (2026-10-14)

1-year change

+24.5 %

Market cap

USD 1.33B

Enterprise value

USD 1.38B

P/E ratio (trailing)

-10.19

P/E ratio (forward)

-10.33

EPS (trailing)

-8.88

EPS (forward)

-8.76

PEG ratio

n/a

Price to book

-25.12

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.66

Employees

109

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Inhibrx Biosciences, Inc. and compare it with other stocks.